Edotreotide

5 trials 2 recruiting VVarious Orphan designation

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

2 Recruiting

1 Completed trials

5 Sponsors

8 Countries

Phase III

Phase II

Phase IV

Phase III: 1 Phase II: 3 Phase IV: 1

Oversight events:

6 temporary halts across 1 trial

View oversight register →

Indications tested

Neuroblastoma 1 Neuroendocrine tumour 1

Sponsors using this IMP

Centre De Lutte Contre Le Cancer Eugene Marquis 1 Centre Hospitalier Universitaire De Bordeaux 1 Centre Hospitalier Universitaire Grenoble Alpes 1 Karolinska University Hospital 1 Voxel S.A. 1

All trials

5 total

A clinical study using a radioactive imaging agent with PET-CT to detect neuroendocrine tumors Not authorised

2025-524050-34-01 Phase III 1 country Voxel S.A.
Prognostic value of early assessment by ⁶⁸Ga-DOTATATE PET/CT for the treatment of well-differentiated grade 2 gastroenteropancreatic neuroen… Pending

2025-524942-87-00 Phase IV 1 country Centre De Lutte Contre Le Cancer Eugene Marquis
Evaluation of the expression of somatostatin receptors in DOTATOC-68Ga PET scans in patients followed for metastatic breast cancer Recruiting

2023-504458-36-02 Phase II 1 country Centre Hospitalier Universitaire Grenoble Alpes
Intra-arterial hepatic (IAH) infusion of radiolabelled somatostatin analogs in GEP-NET patients with dominant liver metastases Recruiting

2024-514785-39-00 Phase II 1 country Centre Hospitalier Universitaire De Bordeaux
A phase II trial of 177Lutetium-DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma LuDO-N Ended

2023-503684-42-00 Phase II 6 countries Karolinska University Hospital

Showing 1–5 of 5 trials

← All drugs A–Z